Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

Neuroprotective properties of GLP-1: theoretical and practical applications

(2011) Jens Juul Holst et al.   CURRENT MEDICAL RESEARCH AND OPINION

Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies

(2010) Vivian A. Fonseca et al.   AMERICAN JOURNAL OF MEDICINE

Effects of γ-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1

(2010) Barry D. Kerr et al.   BIOCHEMICAL PHARMACOLOGY

Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008*

(2010) C. J. Currie et al.   DIABETIC MEDICINE

Strategies to prevent the type 2 diabetes mellitus epidemic

(2010) R. Paul Robertson et al.   Nature Reviews Endocrinology

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

(2010) Scott R Drab   PHARMACOTHERAPY

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties

(2009) Barry D. Kerr et al.   BIOCHEMICAL PHARMACOLOGY

Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis

(2009) P. Flatt et al.   CURRENT DRUG METABOLISM

Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients

(2009) S. T. Knudsen et al.   DIABETOLOGIA

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

(2009) Paula L. McClean et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

KATPChannel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes

(2008) Kasper Aaboe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The incretin system and its role in type 2 diabetes mellitus

(2008) J HOLST et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY